Literature DB >> 7805186

Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.

P Pouna1, S Bonoron-Adèle, G Gouverneur, L Tariosse, P Besse, J Robert.   

Abstract

We have compared the cardiotoxicity of 3 anthracyclines in a model of isolated perfused rat heart using the Langendorff technique. The contractile state and ventricular compliance were studied. Doxorubicin, epirubicin and pirarubicin were perfused at concentrations of 10(-6) and 10(-5) M during 70 min. The cardiac accumulation of the drugs was studied by HPLC. No significant alteration of cardiac functional parameters was observed at 10(-6) M. At 10(-5) M, epirubicin produced a significantly greater alteration of cardiac contractility than doxorubicin, whereas pirarubicin exerted first an inotropic effect followed by a recovery to initial values at the 60th min. Anthracycline accumulation in the heart was dose-dependent; epirubicin accumulated to a 30% greater extent than doxorubicin and pirarubicin heart concentrations were 4-5 times higher than those of doxorubicin at the end of the perfusion. These results suggest that doxorubicin and epirubicin have the same intrinsic cardiac toxicity, and that their distinct clinical cardiotoxicity must be explained by pharmacokinetic differences, whereas pirarubicin is much less cardiotoxic than the other anthracyclines because of different pharmacodynamic properties.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7805186     DOI: 10.1007/BF00686558

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  32 in total

1.  Effects of pirarubicin, an antitumor antibiotic, on the cardiovascular system.

Authors:  S Hirano; N Agata; Y Hara; H Iguchi; M Shirai; H Tone; N Urakawa
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart.

Authors:  K Temma; T Akera; A Chugun; H Kondo; K Hagane; S Hirano
Journal:  Eur J Pharmacol       Date:  1993-04-06       Impact factor: 4.432

3.  Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals.

Authors:  V Lee; A K Randhawa; P K Singal
Journal:  Am J Physiol       Date:  1991-10

4.  4'-O-tetrahydropyranyladriamycin has greater antineoplastic activity than adriamycin in various human tumours in vitro.

Authors:  Y Maehara; Y Sakaguchi; T Kusumoto; H Kusumoto; K Sugimachi
Journal:  Anticancer Res       Date:  1989 Mar-Apr       Impact factor: 2.480

5.  Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients.

Authors:  J Robert; M David; S Huet; J Chauvergne
Journal:  Eur J Cancer Clin Oncol       Date:  1988-08

6.  Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detection.

Authors:  J de Jong; W S Guérand; P R Schoofs; A Bast; W J van der Vijgh
Journal:  J Chromatogr       Date:  1991-09-18

7.  Anthracycline cardiotoxicity: in vivo and in vitro effects on biochemical parameters and heart ultrastructure of the rat.

Authors:  G Cini Neri; B Neri; M Bandinelli; M Del Tacca; R Danesi; R Riccardi
Journal:  Oncology       Date:  1991       Impact factor: 2.935

8.  The isolated perfused rat heart: a model for studying myocardial hypoxia or ischaemia.

Authors:  J de Leiris; D P Harding; S Pestre
Journal:  Basic Res Cardiol       Date:  1984 May-Jun       Impact factor: 17.165

9.  Rapid uptake by cultured tumor cells and intracellular behavior of 4'-O-tetrahydropyranyladriamycin.

Authors:  S Kunimoto; K Miura; Y Takahashi; T Takeuchi; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1983-03       Impact factor: 2.649

10.  Clinical toxicity of 4'-epi-doxorubicin (epirubicin).

Authors:  F Ganzina; N Di Pietro; O Magni
Journal:  Tumori       Date:  1985-06-30
View more
  4 in total

1.  Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?

Authors:  Wenxi Yu; Lina Tang; Feng Lin; Yang Yao; Zan Shen
Journal:  Med Oncol       Date:  2014-11-29       Impact factor: 3.064

Review 2.  Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.

Authors:  A J Coukell; D Faulds
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

3.  Cisplatin and cisplatin analogues perfusion through isolated rat heart: the effects of acute application on oxidative stress biomarkers.

Authors:  Isidora M Stojic; Vladimir I Zivkovic; Ivan M Srejovic; Tamara R Nikolic; Nevena S Jeremic; Jovana N Jeremic; Dragan M Djuric; Nemanja Jovicic; Katarina G Radonjic; Zivadin D Bugarcic; Vladimir L J Jakovljevic; Slobodan S Novokmet
Journal:  Mol Cell Biochem       Date:  2017-08-01       Impact factor: 3.396

4.  Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.